Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

[1]  H. Uramoto,et al.  TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. , 2010, Anticancer research.

[2]  J. Ahn,et al.  The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. , 2010, Lung cancer.

[3]  Wancai Yang,et al.  Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  D. Gandara,et al.  Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy. , 2010 .

[5]  G. Scagliotti,et al.  Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Öhrling,et al.  Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. , 2010, Anticancer research.

[7]  Thomas J. Smith,et al.  American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Bertino,et al.  Cancer research: from folate antagonism to molecular targets. , 2009, Best practice & research. Clinical haematology.

[9]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[10]  X. Qian,et al.  Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine‐based chemotherapy: Evidence from 24 studies , 2008, International journal of cancer.

[11]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Giovannetti,et al.  Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells , 2008, Molecular Pharmacology.

[13]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[14]  A. Tangoku,et al.  Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. , 2007, Anticancer research.

[15]  G. Scagliotti,et al.  Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase , 2006, Cancer.

[16]  J. Walling.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates , 2006, Investigational new drugs.

[17]  P. Bunn,et al.  Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. , 2005, Future oncology.

[18]  Elisa Giovannetti,et al.  Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2005, Molecular Pharmacology.

[19]  R. Haba,et al.  Clinical application of biological markers for treatments of resectable non-small-cell lung cancers , 2005, British Journal of Cancer.

[20]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[21]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[22]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  John J McGuire,et al.  Anticancer antifolates: current status and future directions. , 2003, Current pharmaceutical design.

[25]  G. Peters,et al.  Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. , 2003, Biochemical pharmacology.

[26]  S. Miyoshi,et al.  New prognostic indicator for non‐small‐cell lung cancer, quantitation of thymidylate synthase by real‐time reverse transcription polymerase chain reaction , 2003, International journal of cancer.

[27]  Debabrata Banerjee,et al.  Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. , 2002, Biochimica et biophysica acta.

[28]  M. Fukushima,et al.  Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. , 2002, Lung cancer.

[29]  M. Fukushima,et al.  Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. , 2000, International journal of oncology.

[30]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[31]  H. Miyachi,et al.  Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance. , 1997, International journal of hematology.

[32]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[33]  R M Schultz,et al.  LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. , 1997, Cancer research.

[34]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[35]  J. Maizel,et al.  The functional human dihydrofolate reductase gene. , 1984, The Journal of biological chemistry.

[36]  M. Joerger,et al.  The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. , 2010, Current drug targets.

[37]  M. Fukushima,et al.  A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance , 1998, Cancer.

[38]  S. Groshen,et al.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Waltham,et al.  Molecular mechanisms of resistance to antifolates, a review. , 1995, Acta biochimica Polonica.